The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings

Genetic stratification of Parkinson's disease (PD) patients facilitates gene‐tailored research studies and clinical trials. The objective of this study was to describe the design of and the initial data from the Rostock International Parkinson's Disease (ROPAD) study, an epidemiological observational study aiming to genetically characterize ~10,000 participants.

[1]  C. Shaw,et al.  Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease , 2020, Neurology: Genetics.

[2]  J. Ferreira,et al.  Are genetic and idiopathic forms of Parkinson's disease the same disease? , 2020, Journal of neurochemistry.

[3]  A. Singleton,et al.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.

[4]  E. Tolosa,et al.  LRRK2 in Parkinson disease: challenges of clinical trials , 2020, Nature Reviews Neurology.

[5]  P. Chan,et al.  Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community‐Based 10‐Year Longitudinal Study , 2020, Movement disorders : official journal of the Movement Disorder Society.

[6]  C. Shaw,et al.  Integrated Sequencing & Array Comparative Genomic Hybridization in Familial Parkinson’s Disease , 2019 .

[7]  K. Marder,et al.  Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists , 2019, Genetics in Medicine.

[8]  P. Bauer,et al.  Comprehensive clinical, biochemical and genetic screening reveals four distinct GBA genotypes as underlying variable manifestation of Gaucher disease in a single family , 2019, Molecular genetics and metabolism reports.

[9]  Sonja W. Scholz,et al.  Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.

[10]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[11]  I. König,et al.  Genotype‐phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review , 2018, Movement disorders : official journal of the Movement Disorder Society.

[12]  A. Stepan,et al.  LRRK2 activation in idiopathic Parkinson’s disease , 2018, Science Translational Medicine.

[13]  I. König,et al.  Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  Peng Wang,et al.  The genetics of Parkinson disease , 2018, Ageing Research Reviews.

[15]  T. Strom,et al.  Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease , 2018, Clinical genetics.

[16]  E. Tolosa,et al.  Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry , 2017, Movement disorders : official journal of the Movement Disorder Society.

[17]  A. Lang,et al.  Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.

[18]  T. Foroud,et al.  DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study , 2016, The Lancet Neurology.

[19]  Carlos Cruchaga,et al.  Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson’s Disease , 2016, Molecular Neurodegeneration.

[20]  A. Lang,et al.  Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force , 2016, Movement disorders : official journal of the Movement Disorder Society.

[21]  C. Klein,et al.  Primary familial brain calcification with known gene mutations: a systematic review and challenges of phenotypic characterization. , 2015, JAMA neurology.

[22]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[23]  P. Pollak,et al.  Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers , 2012, Neurology.

[24]  D. Dickson,et al.  Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.

[25]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[26]  T. Foroud,et al.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.

[27]  C. Tanner,et al.  Epidemiology of Parkinson's disease , 2007, Handbook of Clinical Neurology.

[28]  P. Silburn,et al.  Parkinson's disease and family history. , 2006, Parkinsonism & related disorders.

[29]  J. Lupski,et al.  Whole-Exome Sequencing in Familial Parkinson Disease. , 2016, JAMA neurology.

[30]  M. Vidailhet,et al.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.